OmniAb, Inc. (OABI) Reports Q4 Loss, Misses Revenue Estimates

Core Insights - OmniAb, Inc. reported a quarterly loss of $0.11 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.08, representing an earnings surprise of -33.33% [1] - The company posted revenues of $8.38 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 5.14% and down from $10.8 million year-over-year [2] - The stock has underperformed the market, losing about 6.5% since the beginning of the year compared to the S&P 500's decline of 0.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.11 on revenues of $7.43 million, and for the current fiscal year, it is -$0.36 on revenues of $33.64 million [7] - The estimate revisions trend for OmniAb, Inc. was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which OmniAb belongs, is currently in the top 36% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, electroCore, Inc., is expected to report a quarterly loss of $0.35 per share, with revenues projected to be $9.26 million, reflecting a year-over-year increase of 31.4% [9]